Cline Scientific AB adds new orthopedic center to StemCART project

Cline Scientific AB announces that they have begun a partnership with Sahlgrenska University Hospital, orthopedics, for the collection and testing of human knee cartilage tissue as part of the StemCART project. 

During 2022, Cline has been conducting exvivo tests on samples in collaboration with Varberg Hospital and orthopedic surgeons. The addition of a second hospital, Sahlgrenska University Hospital allows Cline more opportunity for conducting studies, in particular for knee cartilage, essential for the next phase of preclinical tests of StemCART.

More about StemCART

StemCART is a preclinical Advanced Therapy Medical Product (ATMP) that aims to revolutionize the treatment of cartilage damage for patients worldwide. To achieve this, Cline will continue preparing for in-human clinical trials, including scaling up production into a GMP facility, developing QA/QC methods, and the necessary safety testing and documentation for a clinical trial application. Cline envisions out-licensing StemCART to a commercial partner following successful phase I trials.

For more information, please contact:

Patrik Sundh, CEO

Email: patrik.sundh@clinescientific.com

Phone: +46 703-585 088

Cline Scientific AB (publ)                                                 Phone: 031-387 55 55
Argongatan 2 C                                                                   Email: info@clinescientific.com
431 53  MÖLNDAL                                                              Website: www.clinescientific.com

About Cline Scientific
Cline Scientific develops advanced cancer diagnostics and regenerative medicine treatments. Cline’s unique patented surface nanotechnology provides solutions to critical challenges for cell-based products and process in Life Science. Cline is driving two projects through to a clinical stage, StemCART - a stem cell therapy for joint repair, and CellRACE- a cancer diagnostic to predict metastasis.